10x Genomics Q2 revenue $114.6M (-1% YoY); net loss $64.5M vs $11.1M loss

10x Genomics, Inc.

2022-Q2 EPS reported -$0.94 revenue$229,105,000

Revenue $114.6M, down 1% YoY; gross margin 76% vs 96% due to $14.7M prior-year royalty reversal.
Operating loss $63.1M (vs $10.3M); net loss $64.5M (vs $11.1M); stock-based comp $36.3M.
FY2022 revenue guidance cut to $500-520M (2-6% growth) from prior expectations.
Headwinds: China lockdowns, European cold-chain logistics delays, execution issues, unfavorable FX.
Launched Fixed RNA Profiling Kit for FFPE; shipped Visium CytAssist; hired Jim Wilbur as CCO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.